Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Weight Loss Drugs: A Game Changer in the Fight Against Obesity - New InsightAce Analytic Report Investigates

This image opens in the lightbox

News provided by

InsightAce Analytic Pvt. Ltd

21 Jun, 2024, 06:00 GMT

Share this article

Share toX

Share this article

Share toX

JERSEY CITY, N.J., June 21, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Weight Loss Drugs Market- (By Drug Type (Prescription and Over-the-counter), By Product (Wegovy, Ozempic, Saxenda, Zepbound, Mounjaro and Others)), By Distribution Channel, By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Weight Loss Drugs Market is valued at US$ 26.3 Bn in 2023, and it is expected to reach US$ 108.9 Bn by 2031, with a CAGR of 19.7% during the forecast period of 2024-2031.

Download Free Sample Report Pages: https://www.insightaceanalytic.com/request-sample/2526 

Weight loss drugs work through various mechanisms in the body to promote weight loss, such as reducing appetite, increasing feelings of fullness, decreasing absorption of nutrients, or increasing calorie expenditure.

The weight loss drugs market is propelled by the escalating global obesity crisis and increasing societal emphasis on health and wellness. As obesity rates surge worldwide, there is a heightened demand for effective weight management solutions. Concurrently, a cultural shift towards prioritizing health and fitness encourages individuals to seek tools to achieve and maintain a healthy weight. These intertwined factors create a robust market for weight loss drugs, motivating pharmaceutical companies to innovate and develop new treatments to address the pressing need for effective weight management solutions.

One significant opportunity in the global weight loss and anti-obesity drugs market lies in developing personalized medicine approaches. As scientific understanding of genetics, metabolism, and individual responses to medications advances, there is a growing potential to tailor weight loss treatments to each person's unique biology. A major restraint of the market revolves around safety concerns, potential side effects, and regulatory hurdles, which are significant factors that pharmaceutical companies must navigate when developing and marketing weight loss medications.

List of Prominent Players in the Weight Loss Drugs Market:

  • Novo Nordisk A/S
  • Eli Lilly & Co.
  • Amgen Inc.
  • Pfizer Inc.
  • Viking Therapeutics Inc.
  • Structure Therapeutics Inc.
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Sandoz International GmbH

Order Full 180 Pages Report @ https://www.insightaceanalytic.com/buy-report/2526 

Market Dynamics:

Drivers:

Obesity stands out as the primary driver in the weight loss drug market due to its alarming global prevalence and associated health risks. With the rising incidence of obesity-related conditions like diabetes, cardiovascular diseases, and certain cancers, there's a growing demand for effective weight management solutions.

According to World Health Organization estimate, the number of adults living with obesity will rise from 1 billion in 2022 to 1.53 billion in 2035. In recent, increase in new treatment options for weight loss is likely to drive the market growth. For instance, currently GLP-1 receptor agonist product like Wegovy and Saxenda is very popular due to high efficacy in weight loss. It also helps to improved glycemic control, reduction in HbA1c levels, etc.

Challenges:

The weight loss drugs market faces several challenges. One major hurdle is the limited long-term efficacy of many weight loss drugs. Weight loss can be not easy to maintain over time, and many drugs on the market offer only short-term benefits. Additionally, safety concerns and potential side effects associated with weight loss drugs pose significant challenges, leading to regulatory scrutiny and sometimes even withdrawal from the market. Another challenge is the high cost of some weight loss drugs, making them inaccessible to many patients.

Regional Trends:

The North American weight loss drugs market is seen to register a major market share in terms of revenue and is estimated to grow at a high CAGR in the near future. Rising concerns about obesity and chronic diseases are prompting individuals to seek effective solutions for weight management. With a substantial portion of the population categorized as overweight or obese, there is a pressing need for interventions that can help address these health issues, resulting in driving the market.

Asia-Pacific is expected to grow significantly during the forecasted period. Rising obesity rates, changing lifestyles, increased disposable income, and growing awareness about health and wellness have all contributed to the growth of this market. Additionally, cultural shifts towards valuing a slim physique and the desire for quick-fix solutions have further propelled the demand for weight loss drugs.

Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/2526 

Recent Developments:

  • In March 2024, Novo Nordisk announced that its new drug, amycretin, for fighting obesity is performing better than its previous drug, Wegovy, in the trials.
  • In November 2023, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's Zepbound (tirzepatide) injection, the first and only obesity treatment that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
  • In December 2023, Roche Holding AG, a Switzerland-based healthcare company, successfully acquired Carmot Therapeutics Inc. for $2.7 billion.

Segmentation of Weight Loss Drugs Market

Weight Loss Drugs Market- By Drug Type

  • Prescription
  • Over-the-counter

Weight Loss Drugs Market- By Drug Class

  • Appetite Suppression
  • Fat Blocking
  • GLP-1 Receptor Agonist
  • Others

Weight Loss Drugs Market- By Product

  • Wegovy
  • Ozempic
  • Saxenda
  • Zepbound
  • Mounjaro
  • Others

Weight Loss Drugs Market- By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Weight Loss Drugs Market- By Region

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/customisation/2526

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:
InsightAce Analytic PVT. LTD
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Follow us on LinkedIn: https://www.linkedin.com/company/insightace-analytic-pvt-ltd/

Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg

Modal title

Also from this source

Functional Service Providers (FSP) Market 2024-2031 | Transform Your Business Strategy with InsightAce Analytic Detailed Report

Functional Service Providers (FSP) Market 2024-2031 | Transform Your Business Strategy with InsightAce Analytic Detailed Report

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Functional Service Providers (FSP) Market- (By...

Sustainable Beauty and Skincare Market will Expand USD 326.8 Billion to 2031- Says Latest InsightAce Analytic Pvt. Ltd. Survey

Sustainable Beauty and Skincare Market will Expand USD 326.8 Billion to 2031- Says Latest InsightAce Analytic Pvt. Ltd. Survey

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Sustainable Beauty and Skincare Market'- By Type (Organic...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.